Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 1Phase 2 1

Status

Completed 14Recruiting 5Unknown 4Active not recruiting 3Terminated 2

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 5Gastrointestinal 1Breast 1

Conditions

Colorectal Neoplasms 75Carcinoma, Hepatocellular 47Ovarian Neoplasms 40Carcinoma, Non-Small-Cell Lung 26Neoplasms 22Fallopian Tube Neoplasms 17Lung Neoplasms 15Breast Neoplasms 13Neoplasm Metastasis 12Glioblastoma 12Endometrial Neoplasms 12Brain Neoplasms 12Colonic Neoplasms 11Triple Negative Breast Neoplasms 10Rectal Neoplasms 10Uterine Cervical Neoplasms 9Liver Neoplasms 9Stomach Neoplasms 8Colorectal Cancer Metastatic 7Pancreatic Neoplasms 6Advanced Solid Tumors 6Recurrence 5Melanoma 5Glioma 5Carcinoma, Renal Cell 5Carcinoma, Ovarian Epithelial 5Biliary Tract Neoplasms 5Solid Tumor 4Meningeal Carcinomatosis 4Adenocarcinoma of Lung 4

Interventions

Paclitaxel 10Carboplatin 6Bevacizumab 5pembrolizumab 4Cyclophosphamide 4olaparib 3liposomal doxorubicin 3fludarabine 3ribociclib 2palbociclib 2mirvetuximab soravtansine 2Topotecan 2Nivolumab 2Letrozole 2Fulvestrant 2Blood Specimen Collection 2trastuzumab deruxtecan 1sacituzumab govitecan 1pegfilgrastim 1niraparib 1lenvatinib 1isoquercitrin 1fludarabine phosphate 1durvalumab 1cemiplimab 1abemaciclib 1Tinzaparin 1Surveys and Questionnaires 1Surgical Procedures, Operative 1SLC25A33 protein, human 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Ovarian Epithelial × Bevacizumab × Clear all
NCT06890338 2026-05-29

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

AbbVie

Phase 2 Recruiting
140 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT06819007 2026-05-26

DO-01

Daiichi Sankyo

Phase 3 Recruiting
582 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT05238922 2026-04-14

Study of INCB123667 in Subjects With Advanced Solid Tumors

Incyte Corporation

Phase 1 Recruiting
604 enrolled
BreastGastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Digestive System Neoplasms

NCT04516447 2026-04-07

MUIR

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

Phase 1 Recruiting
172 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT06469281 2026-02-03

A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers

Regeneron Pharmaceuticals

Phase 1 Recruiting
90 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡